Although monotherapy of anti-EGFR mAbs exhibits a limited efficacy in clinical trials, their combination with radiotherapy and/or chemotherapy has shown promising outcomes in treating advanced squamous cell cancer of head and neck, non small cell lung cancer and colorectal cancers [17]–[22]. Here, EGFR is linked to non-small cell lung carcinoma.